Texas is currently home to 4879 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
Recruiting
The main purpose of this study is to assess the efficacy and safety of volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) who have not progressed after receiving definitive concurrent chemoradiotherapy (cCRT).
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
10/02/2024
Locations: Research Site, Austin, Texas
Conditions: Locally Advanced Head and Neck Squamous Cell Carcinoma
Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers
Recruiting
To learn if sacituzumab govitecan can help to control salivary gland cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/02/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Gland, Salivary Gland Cancers
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
Recruiting
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/02/2024
Locations: Clinical Trial Network, Houston, Texas
Conditions: HER2-positive Advanced Solid Tumor
Identifying Decision Making Needs for Older Adult Women with Stage I-III Breast Cancer Considering Neoadjuvant or Adjuvant Chemotherapy
Recruiting
This study collects information and identifies decision making needs for older adult women with stage I-III breast cancer considering neoadjuvant and adjuvant chemotherapy. Using this information, a decision support tool is then developed to provide patients and physicians with tailored information regarding the risks and benefits of chemotherapy and values clarification to support high-quality, shared decision. Subsequently, the decision support tool will be tested amongst older patients with e... Read More
Gender:
FEMALE
Ages:
65 years and above
Trial Updated:
10/02/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia
Recruiting
Pegylated arginine deiminase (ADI-PEG 20) will be combined with venetoclax and azacitidine for treatment of subjects with previously treated or untreated with high risk factor acute myeloid leukemia (AML). Venetoclax and azacitidine are front-line therapy for such patients, and ADI-PEG 20 will be added to this regimen in a phase IA/B study.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
10/02/2024
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Acute Myeloid Leukemia, Adult
Evaluating Pathways Mutual Gaze Protocol on Social Skills in Young Children Suspected of Autism
Recruiting
Purpose of the Study: The goal of this clinical trial is to find out if a technique called the "mutual gaze procedure," used in Pathways Early Intervention (Pathways), is the key to helping improve social communication, language, and everyday skills in young children (16-30 months old) who are at high risk for autism, particularly those from diverse cultural and language backgrounds. What Will Happen: Researchers will compare two versions of the Pathways Intervention: * Version 1: Includes mut... Read More
Gender:
ALL
Ages:
Between 16 months and 30 months
Trial Updated:
10/01/2024
Locations: University of Texas at Dallas, Richardson, Texas
Conditions: Autism
Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations
Recruiting
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-200 in cancers with FGFR2 activating gene alterations, including unresectable locally advanced/metastatic intrahepatic cholangiocarcinoma and other advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/01/2024
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Locally Advanced Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Solid Tumor, Metastatic Cholangiocarcinoma
Phase 1b Combo w/ Ribociclib, Alpelisib, or Everolimus
Recruiting
This is a Phase 1b open-label, 2-part study in 3 treatment groups. The 3 treatment groups are as follows: Treatment Group 1: OP-1250 in combination with ribociclib (KISQALI®, Novartis Pharmaceuticals Corporation). Treatment Group 2: OP-1250 in combination with alpelisib (PIQRAY®, Novartis Pharmaceuticals Corporation). Treatment Group 3: OP-1250 in combination with everolimus.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/01/2024
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Metastatic Breast Cancer, Advanced Breast Cancer, HER2-negative Breast Cancer, ER-positive Breast Cancer, Breast Cancer
SMR Stemless Reverse Vs SMR Reverse Shoulder System
Recruiting
The SMR Stemless Reverse is intended for total, primary shoulder joint replacement by reducing pain and restoring shoulder articular mobility function. This is a prospective, multi-center, randomized, controlled trial to demonstrate non-inferiority of the SMR Stemless Reverse to the SMR Reverse Shoulder System. Patients with joint dysfunction who continue to experience significant symptoms despite an appropriate course of non-operative management are eligible. Patients will be considered enroll... Read More
Gender:
ALL
Ages:
22 years and above
Trial Updated:
10/01/2024
Locations: University of Texas- Health Science Center, San Antonio, Texas
Conditions: Arthroplasty, Replacement
Molecular and Immunohistochemical Profiling of Tumors in Patients with Parathyroid Tumors
Recruiting
This trial studies molecular and immunohistochemical profiling of tumors in patients with parathyroid tumors. Studying molecular and immunohistochemical profiling of tumors may help doctors avoid inconsistencies in diagnosis, unnecessary or incomplete surgery, surgical morbidity, psychological stress, and inadequate follow up.
Gender:
ALL
Ages:
All
Trial Updated:
10/01/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Parathyroid Gland Adenoma, Parathyroid Gland Atypical Adenoma, Parathyroid Gland Carcinoma, Primary Hyperparathyroidism
ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome
Recruiting
The purpose of the study is to develop a prognostic index model for the rare disease of mycosis fungoides and sezary syndrome. This will be done by collecting standardized clinical data at various institutions. The investigators hope this will enable the identification of low- and high-risk groups for survival in order to improve patient care and outcome.
Gender:
ALL
Ages:
All
Trial Updated:
10/01/2024
Locations: University of Texas Southwestern, Dallas, Texas
Conditions: Mycosis Fungoides, Non-Hodgkin's Lymphoma
Safety of Microporous Annealed Particle (MAP) Wound Matrix in Patients with Clean Surgical Wounds.
Recruiting
A randomized, open-label, investigational safety evaluation of the Microporous Annealed Particle (MAP) Wound Matrix (TT101) device as a volumetric biomaterial scaffold applied to clean wounds after skin cancer surgery with Mohs micrographic surgery (MMS) compared to control.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
09/30/2024
Locations: Studies in Dermatology, Cypress, Texas
Conditions: Wound Heal